Kuros Bioscience GAAP EPS of -$0.05, revenue of $63.48M misses by $19.35M; reaffirms FY outlook
Source: SeekingAlpha
2025-08-14 09:27:45 ET
More on Kuros Bioscience
Read the full article on Seeking Alpha
For further details see:
Kuros Bioscience GAAP EPS of -$0.05, revenue of $63.48M misses by $19.35M; reaffirms FY outlook
Kuros Biosciences Ltd
NASDAQ: CSBTF
CSBTF Trading
0.0% G/L:
$32 Last:
250 Volume:
$32 Open:
CSBTF Latest News
March 10, 2026 02:00:00 am
Kuros Biosciences delivers 72% year-over-year sales growth, reaching USD 146.1 million for 2025
January 13, 2026 01:00:00 am
Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences
December 02, 2025 01:00:00 am
Kuros Biosciences announces enrollment of first patient in ASTRA study - A global, prospective, randomized, multi-center clinical trial in foot and ankle fusion
November 26, 2025 01:00:00 am
Kuros Biosciences to present at the Piper Sandler 37th Annual Healthcare Conference
